Condition
Non Small Cell Lung Cancer (NSCLC)|Malignant Pleural Mesothelioma (MPM)
Estimated Enrollment: 32
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 2014-53
Study First Received: September 11, 2015
Last Updated: September 18, 2015
Estimated Primary Completion Date: August 2018
Primary Outcome Measures:
Phase IA : Treatment-related hematological toxicities (neutropenia) of grade 3-4 as assessed by CTCAE v4.0|Phase IB : Objective response rate according to RECIST1.1 for NSCLC and RECIST1.1 modified for MPM
Sponsors and Collaborators:
Assistance Publique Hopitaux De Marseille
Website Link: https://ClinicalTrials.gov/show/NCT02555007
